Please login to the form below

Not currently logged in
Email:
Password:

daclatasvir

This page shows the latest daclatasvir news and features for those working in and with pharma, biotech and healthcare.

Gilead gets OK for three-in-one hep C therapy in US

Gilead gets OK for three-in-one hep C therapy in US

Other NS5A inhibitors on the market for HCV include Gilead's ledipasvir, Bristol-Myers Squibb's daclatasvir, AbbVie's dasabuvir and Merck &Co's elbasvir.

Latest news

More from news
Approximately 6 fully matching, plus 25 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Alzheimers incidence
A roadmap to the successful treatment of Alzheimer’s disease
Building on past research to learn more about the disease and how to treat it...
Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...

Infographics